Biomarkers in kidney fibrosis: Are they useful¿

Kidney International Supplements

Volumn 4, Issue 1, 2014, Pages 79-83

  Wong, Muh Geot ^a   Pollock, Carol A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

biomarkers; chronic kidney disease; diabetic nephropathy; fibrosis; transforming growth factor 1

Indexed keywords

OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FIBROSING ALVEOLITIS; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW;

EID: 84908503776     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2014.15     Document Type: Short Survey

References (27)

1. Deloitte Access Economics. Two of a Kind. http://www.deloitte.com/view/ en-AU/au/industries/Lifesciencesandhealth/, 2011.
2. USRDS. Cost of ESRD. In: Atlas of CKD & ESRD, Vol 2, Chapter 11. USRDS: Ann Arbor, MI, USA, 2013, pp 325-332.
3. Lemley KV. An introduction to biomarkers: applications to chronic kidney disease. Pediatr Nephrol 2007; 22: 1849-1859.
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
5. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340.
6. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8: 301-306.
7. Thompson A. Proteinuria as a surrogate end point-more data are needed. Nat Rev Nephrol 2012; 8: 306-309.
8. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004; 4: 309-314.
9. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006; 355: 2615-2617.
10. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935.
11. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
12. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
13. Pencina MJ, D'Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
14. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997; 16: 981-991.
15. Pepe MS, Janes H, Longton G et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-890.
16. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol 2011; 173: 1327-1335.
17. Akaike H. "A new look at the statistical model identification". IEEE Trans Automat Contr 1974; 6: 716-723.
18. Schwarz GE. "Estimating the dimension of a model". Ann Stat 1978; 2: 461-464.
19. Suthanthiran M, Gerber LM, Schwartz JE et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009; 76: 72-80.
20. Zitouni K, Harry DD, Nourooz-Zadeh J et al. Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. Kidney Int 2005; 67: 1993-1998.
21. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21: 568-573.
22. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696.
23. Wong MG, Perkovic V, Woodward M et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2013; 83: 278-284.
24. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010; 119: S22-S26.
25. Ernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int 2009; 76: 262-276.
26. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515.
27. Gohda T, Niewczas MA, Ficociello LH et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524.